Top Companies in the Albumin Pharma Market
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Grifols S.A.
- Octapharma AG
- Kedrion Biopharma
- Shire (part of Takeda)
- Thermo Fisher Scientific (recombinant albumin for biopharma use)
- Albumedix Ltd. (Novozymes)
- Baxter International Inc.
- Bio Products Laboratory (BPL)
- Sanquin Plasma Products
- Hualan Biological Engineering Inc.
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
- Wuhan Institute of Biological Products Co., Ltd.
- Shanghai RAAS Blood Products Co., Ltd.
- InVitria (recombinant albumin specialist)
- Green Cross Corporation (GC Pharma)
- China Biologic Products Holdings, Inc.
- Reliance Life Sciences (India)
- Apotex Pharmachem Inc.
Market Forecast
The global albumin pharma market size marked US$ 6.77 billion in 2024 and is forecast to experience consistent growth, reaching US$ 7.15 billion in 2025 and US$ 11.72 billion by 2034 at a CAGR of 5.65%.
Albumin Pharma Market Trends
Expansion in Emerging Markets
Expansion in emerging markets significantly drives the growth of the albumin pharmaceutical market by increasing access to life-saving treatments, boosting production capabilities, and fostering innovation. Countries like India, China, Brazil, and Mexico are experiencing a rise in chronic diseases such as liver cirrhosis, kidney disorders, and cardiovascular conditions, leading to higher demand for albumin-based therapies. Additionally, these regions are investing in healthcare infrastructure and plasma fractionation facilities, improving the availability of albumin products.
For instance,
- In 2025, India aimed to diversify its pharmaceutical export markets by boosting trade with Russia, Brazil, and the Netherlands amid rising concerns over potential U.S. tariffs. This strategic move highlights the growing importance of emerging markets in the global pharmaceutical landscape.
Value Chain Analysis for The Albumin Pharma Market
Research & Development (R&D)
- Target Identification & Discovery – Identifying clinical needs and albumin’s therapeutic potential.
- Preclinical Research – Studying pharmacodynamics, pharmacokinetics, and safety in vitro and in animal models.
- Formulation Development – Designing plasma-derived or recombinant albumin products, including drug delivery systems.
Key Organizations: Grifols, S.A., CSL Behring, Baxter International, Novozymes Biopharma, etc.
Clinical Trial & Approval Steps
- Phase I Trials – Safety assessment in healthy volunteers.
- Phase II Trials – Efficacy and dose optimization in patients.
- Phase III Trials – Large-scale validation of safety and effectiveness.
- Regulatory Approval – Submission to authorities for market authorization.
Key Regulatory & Clinical Organizations: U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, Clinical Research Organizations (CROs) such as IQVIA and Parexel
Patient Support & Services
- Distribution to Hospitals & Clinics – Ensuring timely supply of albumin products.
- Clinical Education & Training – Educating healthcare professionals on proper use.
- Patient Assistance Programs – Financial support, dosage guidance, and follow-up care.
Key Organizations & Programs: Grifols Patient Assistance Programs, CSL Behring Patient Support Services, Baxter Healthcare Patient Support Programs
Latest Announcement by Industry Leaders
In June 2025, Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma, stated that a subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") declared that the FDA-approved immunotherapy LYMPHIR, which treats adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), is almost ready for commercialization. Since all significant launch-enabling activities are currently in progress, the company believes it is now operationally ready to move from a development-stage enterprise to a fully integrated commercial organization. The last preparations are underway for LYMPHIR's second-half 2025 U.S. launch.
Recent Developments in the Albumin Pharma Market
- In May 2025, Shilpa Medicare Limited declared that its 100% subsidiary, Shilpa Biocare Private Limited, has out-licensed its flagship product, Recombinant Human Albumin, for commercialization throughout the European market as part of a strategic alliance with Orion Corporation (Orion), a well-known pharmaceutical company with facilities in Finland.
- In April 2025, InVitria introduced Optibumin 25, a 25% recombinant human serum albumin solution. This product is designed for use in closed-system biomanufacturing processes, offering an animal-origin-free, GMP-compliant alternative to plasma-derived albumin. Its development addresses the growing demand for safe, consistent, and scalable albumin sources in the production of biologics and vaccines.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
